A Placebo-Controlled Trial of Interferon Gamma-1b in Patients with Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive, fatal disease with no known efficacious therapy. METHODS: In a double-blind, multinational trial, we randomly assigned 330 patients with idiopathic pulmonary fibrosis that was unresponsive to corticosteroid therapy to receive subcutaneous interferon gamma-1b or placebo. RESULTS: Over a median of 58 weeks, interferon gamma-1b therapy did not significantly affect the primary end point of progression-free survival, defined as the time to disease progression or death, and no significant treatment effect was observed on measures of lung function, gas exchange, or the quality of life. Ten percent of patients in the interferon gamma-1b group died, as compared with 17 percent of patients in the placebo group (P=0.08). Treatment with interferon gamma-1b was associated with more frequent constitutional symptoms. However, the rates of treatment adherence and premature discontinuation of treatment were similar in the two groups. More pneumonias were reported among patients in the interferon gamma-1b group, but the incidence of severe or life-threatening respiratory tract infections was similar in the two groups. CONCLUSIONS: In a well-defined population of patients with idiopathic pulmonary fibrosis, interferon gamma-1b did not affect progression-free survival, pulmonary function, or the quality of life. Owing to the size and duration of the trial, a clinically significant survival benefit could not be ruled out.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, systemic administration of recombinant IFNγ (which would simulate the presence of Th1 biology) and monoclonal antibody-mediated neutralization of IL-13 (which would specifically target Th2 responses) failed to demonstrate efficacy in randomized, placebo-controlled trials of patients with IPF (141, 142).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [141]
Citations
Cites
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus Statement
(2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.161.2.ats3-00 · Cited by 2,628
Nathan, C. F., Murray, H. W., Wiebe, M. E., & Rubin, B. Y. (1983) · The Journal of experimental medicine · doi:10.1084/jem.158.3.670 · Cited by 1,962
Mahler, D. A., Weinberg, D. H., Wells, C. K., & Feinstein, A. R. (1984) · Chest · doi:10.1378/chest.85.6.751 · Cited by 1,292
Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary Fibrosis
BJORAKER, J. A., RYU, J. H., EDWIN, M. K., MYERS, J. L., TAZELAAR, H. D., SCHROEDER, D. R., & OFFORD, K. P. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.1.9704130 · Cited by 1,039
Editorial: Cerebral Palsy—the International Consensus Statement
Clements, R. V., & Simanowitz, A. (2000) · Clinical Risk · doi:10.1177/135626220000600401 · Cited by 856
Predicting Survival in Idiopathic Pulmonary Fibrosis
KING, T. E., TOOZE, J. A., SCHWARZ, M. I., BROWN, K. R., & CHERNIACK, R. M. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.164.7.2003140 · Cited by 853
Self-citationinternational consensus statement
Clements, R. V., & Simanowitz, A. (2000) · Cited by 852
Gajewski, T. F., & Fitch, F. W. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.140.12.4245 · Cited by 834
Broekelmann, T. J., Limper, A. H., Colby, T. V., & McDonald, J. A. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.15.6642 · Cited by 794
Research works printed but not linked: 2
- Okada T, 1993, Lymphokine Cytokine Res, 12, 87
- 10.1002/(sici)1096-9896(199903)187:4<475::aid-path268>3.0.co;2-n · doi:10.1002/(sici)1096-9896(199903)187:4<475::aid-path268>3.0.co;2-n
Cited by
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationKing, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationProtein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationClinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Self-citationFibrosis–a common pathway to organ injury and failure
Rockey, D. C., Bell, P. D., & Hill, J. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1300575 · Cited by 1,428
Incidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310
Self-citationInterstitial Lung Disease in Systemic Sclerosis: A Simple Staging System
Goh, N. S. L., Desai, S. R., Veeraraghavan, S., Hansell, D. M., Copley, S. J., Maher, T. M., Corte, T. J., Sander, C. R., Ratoff, J., Devaraj, A., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200706-877oc · Cited by 1,230
“Mortality, disease progression (‘‘time to decline’’ in either FVC levels of >10% from baseline or DLCO levels of >15% from baseline) and ‘‘progression-free survival’’ were quantified from the date of HRCT, as previously described (10, 13 ) (see online supplement).”
MethodOrens, J. B., Estenne, M., Arcasoy, S., Conte, J. V., Corris, P., Egan, J. J., Egan, T., Keshavjee, S., Knoop, C., Kotloff, R., et al. (2006) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2006.03.011 · Cited by 1,073
Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity
Cottin, V., Nunes, H., Brillet, P.-Y., Delaval, P., Devouassoux, G., Tillie-Leblond, I., Israel-Biet, D., Court-Fortune, I., Valeyre, D., & Cordier, J.-F. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00021005 · Cited by 1,004
“Interferon-c is poorly effective in IPF [ 25 ], causes emphysema in mice [26], and thus is not advisable in CPFE.”
Moeller, A., Ask, K., Warburton, D., Gauldie, J., & Kolb, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.08.011 · Cited by 1,007
Willis, B. C., Liebler, J. M., Luby-Phelps, K., Nicholson, A. G., Crandall, E. D., du Bois, R. M., & Borok, Z. (2005) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)62351-6 · Cited by 951
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
“In cases AFFILIATIONS *Dept of Respiratory Medicine and Allergy, Tosei General Hospital, Aichi, #Dept of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, "Dept of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Yokohama, +Fourth Dept of Internal Medicine, Nippon Medica…”
BackgroundSelf-citationHigh-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042976 · Cited by 964
Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
“In a recent study, there appeared to be significant episodes of acute respiratory decompensations preceding death in patients with progressive IPF (6).”
BackgroundSelf-citationInterstitial lung disease guideline
Wells, A. U., Hirani, N., & on behalf of the BTS Interstitial Lung Disease Guideline Group, A. S. O. T. B. T. S. S. O. C. C. (2008) · Thorax · doi:10.1136/thx.2008.101691 · Cited by 866
“Nagai S., Kitaichi M., Hamada K. et al. Hospital based historical cohort study of 234 histologically proven Japanese patients with IPF.”
BackgroundPirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
BUILD-3: A Randomized, Controlled Trial of Bosentan in Idiopathic Pulmonary Fibrosis
King, T. E., Brown, K. K., Raghu, G., du Bois, R. M., Lynch, D. A., Martinez, F., Valeyre, D., Leconte, I., Morganti, A., Roux, S., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1874oc · Cited by 718
Self-citationThe Impact of TGF-β on Lung Fibrosis: From Targeting to Biomarkers
Fernandez, I. E., & Eickelberg, O. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201203-023aw · Cited by 679
Interferon-gamma (IFN-γ): Exploring its implications in infectious diseases
Kak, G., Raza, M., & Tiwari, B. K. (2018) · Biomolecular Concepts · doi:10.1515/bmc-2018-0007 · Cited by 617
The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
“Overview Using data from a recently completed clinical trial (3), we performed a series of exploratory analyses of physiologic variables, dyspnea measures, hospitalizations, and characteristics of mortality in patients randomly assigned to receive placebo.”
BackgroundMethodInfluentialSelf-citationNoth, I., Zhang, Y., Ma, S.-F., Flores, C., Barber, M., Huang, Y., Broderick, S. M., Wade, M. S., Hysi, P., Scuirba, J., et al. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70045-6 · Cited by 614
Rheumatoid Arthritis–Interstitial Lung Disease–associated Mortality
Olson, A. L., Swigris, J. J., Sprunger, D. B., Fischer, A., Fernandez-Perez, E. R., Solomon, J., Murphy, J., Cohen, M., Raghu, G., & Brown, K. K. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201004-0622oc · Cited by 544
Self-citationInflammation and immunity in IPF pathogenesis and treatment
Heukels, P., Moor, C. C., von der Thüsen, J. H., Wijsenbeek, M. S., & Kool, M. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2018.12.015 · Cited by 517
High-Resolution Computed Tomography in Idiopathic Pulmonary Fibrosis: Diagnosis and Prognosis
Lynch, D. A., Godwin, J. D., Safrin, S., Starko, K. M., Hormel, P., Brown, K. K., Raghu, G., King, T. E., Bradford, W. Z., Schwartz, D. A., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200412-1756oc · Cited by 547
“The present study sought to address these issues by using data from a prospective, randomized, double-blind, placebo-controlled clinical trial evaluating the use of IFN- 1b in patients with IPF (7).”
Self-citationMolecular Targets in Pulmonary Fibrosis
Scotton, C. J., & Chambers, R. C. (2007) · Chest · doi:10.1378/chest.06-2568 · Cited by 538
King, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citationdu Bois, R. M., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., King, T. E., Lancaster, L., Noble, P. W., Sahn, S. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201105-0840oc · Cited by 527
“The designs of these trials are described in detail elsewhere (20, 21).”
MethodSelf-citationIdiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology
Vancheri, C., Failla, M., Crimi, N., & Raghu, G. (2010) · European Respiratory Journal · doi:10.1183/09031936.00077309 · Cited by 464
Self-citationOxidative stress and glutathione in TGF-β-mediated fibrogenesis
Liu, R.-M., & Gaston Pravia, K. A. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.09.026 · Cited by 469
Oku, H., Shimizu, T., Kawabata, T., Nagira, M., Hikita, I., Ueyama, A., Matsushima, S., Torii, M., & Arimura, A. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.06.046 · Cited by 436
Mortality from Pulmonary Fibrosis Increased in the United States from 1992 to 2003
Olson, A. L., Swigris, J. J., Lezotte, D. C., Norris, J. M., Wilson, C. G., & Brown, K. K. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-044oc · Cited by 435
“In the late 1990s, the first large, multinational, therapeutic trial for IPF was conceptualized and began enrolling patients—a factor that, no doubt, raised awareness for the disease ( 18 ).”
BackgroundResultSelf-citationOxidative Stress in Pulmonary Fibrosis: A Possible Role for Redox Modulatory Therapy
Kinnula, V. L., Fattman, C. L., Tan, R. J., & Oury, T. D. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200501-017pp · Cited by 437
Classification and Natural History of the Idiopathic Interstitial Pneumonias
Kim, D. S., Collard, H. R., & King, T. E. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200601-005tk · Cited by 431
Self-citationClinical and Pathologic Features of Familial Interstitial Pneumonia
Steele, M. P., Speer, M. C., Loyd, J. E., Brown, K. K., Herron, A., Slifer, S. H., Burch, L. H., Wahidi, M. M., Phillips, J. A., Sporn, T. A., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200408-1104oc · Cited by 432
“More importantly, patients with IIP often have a delay in diagnosis, and clinical trials testing novel types of treatment for IPF/UIP suggest the importance of early diagnosis and treatment ( 40 ), These individuals may be ideal candidates for early intervention trials.”
BackgroundSelf-citationAscertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis
du Bois, R. M., Weycker, D., Albera, C., Bradford, W. Z., Costabel, U., Kartashov, A., Lancaster, L., Noble, P. W., Raghu, G., Sahn, S. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201011-1790oc · Cited by 424
Self-citationMolecular and cellular mechanisms of pulmonary fibrosis
Todd, N. W., Luzina, I. G., & Atamas, S. P. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-11 · Cited by 418
Meltzer, E. B., & Noble, P. W. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-8 · Cited by 407
“New insight into the natural history of IPF has been gleaned from secondary analysis of the placebo groups assembled for recent multi-center clinical trials [21-23].”
Self-citationSix-Minute-Walk Distance Predicts Waiting List Survival in Idiopathic Pulmonary Fibrosis
Lederer, D. J., Arcasoy, S. M., Wilt, J. S., D'Ovidio, F., Sonett, J. R., & Kawut, S. M. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200604-520oc · Cited by 402
Morell, F., Villar, A., Montero, M.-Á., Muñoz, X., Colby, T. V., Pipvath, S., Cruz, M.-J., & Raghu, G. (2013) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(13)70191-7 · Cited by 392
Self-citationBurnham, E. L., Janssen, W. J., Riches, D. W. H., Moss, M., & Downey, G. P. (2014) · European Respiratory Journal · doi:10.1183/09031936.00196412 · Cited by 365
Cytokine mediated tissue fibrosis
Borthwick, L. A., Wynn, T. A., & Fisher, A. J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.09.014 · Cited by 375
Imatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results
Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., & Schroeder, D. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0964oc · Cited by 373
Long-term Course and Prognosis of Idiopathic Pulmonary Fibrosis in the New Millennium
Nathan, S. D., Shlobin, O. A., Weir, N., Ahmad, S., Kaldjob, J. M., Battle, E., Sheridan, M. J., & du Bois, R. M. (2011) · Chest · doi:10.1378/chest.10-2572 · Cited by 369
Treatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial
Raghu, G., Brown, K. K., Costabel, U., Cottin, V., du Bois, R. M., Lasky, J. A., Thomeer, M., Utz, J. P., Khandker, R. K., McDermott, L., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1446oc · Cited by 370
Self-citationIdiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?
Maher, T. M., Wells, A. U., & Laurent, G. J. (2007) · European Respiratory Journal · doi:10.1183/09031936.00069307 · Cited by 341
“The limitations of this model have been reflected in disappointing trials of therapy targeting individual disease pathways [ 26 , 27].”
Clinical Advances in the Diagnosis and Therapy of the Interstitial Lung Diseases
King, T. E. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200503-483oe · Cited by 330
Self-citationBest, A. C., Meng, J., Lynch, A. M., Bozic, C. M., Miller, D., Grunwald, G. K., & Lynch, D. A. (2008) · Radiology · doi:10.1148/radiol.2463062200 · Cited by 323
“Because of the documented accuracy of using CT images to establish a confident diagnosis of IPF (12), CT is often used in place of biopsy as an entry criterion in clinical trials (11).”
BackgroundMethodEffects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis
NISHIYAMA, O., KONDOH, Y., KIMURA, T., KATO, K., KATAOKA, K., OGAWA, T., WATANABE, F., ARIZONO, S., NISHIMURA, K., & TANIGUCHI, H. (2008) · Respirology · doi:10.1111/j.1440-1843.2007.01205.x · Cited by 316
The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis
Desai, O., Winkler, J., Minasyan, M., & Herzog, E. L. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00043 · Cited by 314
“org March 2018 | Volume 5 | Article 43 IFNγ (which would simulate the presence of Th1 biology) and monoclonal antibody-mediated neutralization of IL-13 (which would specifically target Th2 responses) failed to demonstrate efficacy in randomized, placebo-controlled trials of patients with IPF (141, 142).”
BackgroundPhysiology Is a Stronger Predictor of Survival than Pathology in Fibrotic Interstitial Pneumonia
Jegal, Y., Kim, D. S., Shim, T. S., Lim, C.-M., Do Lee, S., Koh, Y., Kim, W. S., Kim, W. D., Lee, J. S., Travis, W. D., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200403-331oc · Cited by 308
Baseline BAL Neutrophilia Predicts Early Mortality in Idiopathic Pulmonary Fibrosis
Kinder, B. W., Brown, K. K., Schwarz, M. I., Ix, J. H., Kervitsky, A., & King, T. E. (2008) · Chest · doi:10.1378/chest.07-1948 · Cited by 302
Self-citationMiller, C. H. T., Maher, S. G., & Young, H. A. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05069.x · Cited by 303
Regulation of pulmonary fibrosis by chemokine receptor CXCR3
Jiang, D., Liang, J., Hodge, J., Lu, B., Zhu, Z., Yu, S., Fan, J., Gao, Y., Yin, Z., Homer, R., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci16861 · Cited by 303
“ries that have occurred at different times over a long period (2, 3).”
Self-citationSavin, I. A., Zenkova, M. A., & Sen’kova, A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314959 · Cited by 279
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
Hyzy, R., Huang, S., Myers, J., Flaherty, K., & Martinez, F. (2007) · Chest · doi:10.1378/chest.07-0299 · Cited by 277
Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review
Swigris, J. J. (2005) · Thorax · doi:10.1136/thx.2004.035220 · Cited by 275
“in the IPF group was 45.3% of the normal predicted value and 14 IPF patients were using supplemental oxygen. In another cross sectional study, Martinez and colleagues assessed HRQL in 30 patients with moderately severe IPF using the SF-36.”
MethodInfluentialAccelerated Variant of Idiopathic Pulmonary Fibrosis: Clinical Behavior and Gene Expression Pattern
Selman, M., Carrillo, G., Estrada, A., Mejia, M., Becerril, C., Cisneros, J., Gaxiola, M., Pérez-Padilla, R., Navarro, C., Richards, T., et al. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000482 · Cited by 270
Self-citationTherapeutic targets in lung tissue remodelling and fibrosis
Liu, G., Philp, A. M., Corte, T., Travis, M. A., Schilter, H., Hansbro, N. G., Burns, C. J., Eapen, M. S., Sohal, S. S., Burgess, J. K., et al. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107839 · Cited by 249
Natural killer cells in infection and inflammation of the lung
Culley, F. J. (2009) · Immunology · doi:10.1111/j.1365-2567.2009.03167.x · Cited by 244
Strategies for treating idiopathic pulmonary fibrosis
du Bois, R. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2958 · Cited by 251
“In a subsequent large, multicentre, randomized double-blind, placebo controlled investigation into the safety and efficacy of IFNγ, 330 patients were randomized in a ratio of 1:1 to receive either IFNγ1b or placebo subcutaneously three times weekl”
MethodIdiopathic Pulmonary Fibrosis: Pathogenesis and Therapeutic Approaches
Selman, M., Thannickal, V. J., Pardo, A., Zisman, D. A., Martinez, F. J., & Lynch, J. P. (2004) · Drugs · doi:10.2165/00003495-200464040-00005 · Cited by 244
Idiopathic Pulmonary Fibrosis: Clinically Meaningful Primary Endpoints in Phase 3 Clinical Trials
Raghu, G., Collard, H. R., Anstrom, K. J., Flaherty, K. R., Fleming, T. R., King, T. E., Martinez, F. J., & Brown, K. K. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201201-0006pp · Cited by 242
Self-citationAhluwalia, N., Shea, B. S., & Tager, A. M. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201403-0509pp · Cited by 235
Prasse, A., Pechkovsky, D. V., Toews, G. B., Schäfer, M., Eggeling, S., Ludwig, C., Germann, M., Kollert, F., Zissel, G., & Müller‐Quernheim, J. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22559 · Cited by 227
Role of Galectin-3 in Human Pulmonary Fibrosis
Nishi, Y., Sano, H., Kawashima, T., Okada, T., Kuroda, T., Kikkawa, K., Kawashima, S., Tanabe, M., Goto, T., Matsuzawa, Y., et al. (2007) · Allergology International · doi:10.2332/allergolint.o-06-449 · Cited by 226
Regional chest wall volumes during exercise in chronic obstructive pulmonary disease
Aliverti, A. (2004) · Thorax · doi:10.1136/thorax.2003.011494 · Cited by 226
King, T. E., Safrin, S., Starko, K. M., Brown, K. K., Noble, P. W., Raghu, G., & Schwartz, D. A. (2005) · Chest · doi:10.1378/chest.127.1.171 · Cited by 222
Self-citationSerum Surfactant Protein-A Is a Strong Predictor of Early Mortality in Idiopathic Pulmonary Fibrosis
Kinder, B. W., Brown, K. K., McCormack, F. X., Ix, J. H., Kervitsky, A., Schwarz, M. I., & King, T. E. (2009) · Chest · doi:10.1378/chest.08-2209 · Cited by 209
Self-citationNovel therapeutic approaches for pulmonary fibrosis
Datta, A., Scotton, C. J., & Chambers, R. C. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01247.x · Cited by 202
“Post hoc analysis of a second, similarly designed trial (Raghu et al., 2004), suggested that patients with relatively well-preserved lung function may have a survival benefit with IFN-g treatment.”
MethodSide Effects of Cytokines Approved for Therapy
Baldo, B. A. (2014) · Drug Safety · doi:10.1007/s40264-014-0226-z · Cited by 190
Paterniti, M. O., Bi, Y., Rekić, D., Wang, Y., Karimi-Shah, B. A., & Chowdhury, B. A. (2017) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201606-458oc · Cited by 194
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis
Richeldi, L., Ryerson, C. J., Lee, J. S., Wolters, P. J., Koth, L. L., Ley, B., Elicker, B. M., Jones, K. D., King, T. E., Ryu, J. H., et al. (2012) · Thorax · doi:10.1136/thoraxjnl-2011-201184 · Cited by 185
Self-citationWijeysundera, D. N., Austin, P. C., Hux, J. E., Beattie, W. S., & Laupacis, A. (2009) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2008.07.006 · Cited by 184
Early Interstitial Lung Disease in Familial Pulmonary Fibrosis
Rosas, I. O., Ren, P., Avila, N. A., Chow, C. K., Franks, T. J., Travis, W. D., McCoy, J. P., May, R. M., Wu, H.-P., Nguyen, D. M., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200702-254oc · Cited by 180
Pharmacology and therapeutic potential of interferons
George, P. M., Badiger, R., Alazawi, W., Foster, G. R., & Mitchell, J. A. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.03.006 · Cited by 176
Goh, N. S. L., Veeraraghavan, S., Desai, S. R., Cramer, D., Hansell, D. M., Denton, C. P., Black, C. M., du Bois, R. M., & Wells, A. U. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22696 · Cited by 177
Current Perspectives on the Treatment of Idiopathic Pulmonary Fibrosis
Walter, N., Collard, H. R., & King, T. E. (2006) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200602-016tk · Cited by 174
Self-citationCXCL11 Attenuates Bleomycin-induced Pulmonary Fibrosis via Inhibition of Vascular Remodeling
Burdick, M. D., Murray, L. A., Keane, M. P., Xue, Y. Y., Zisman, D. A., Belperio, J. A., & Strieter, R. M. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200409-1164oc · Cited by 164
“Our findings have demonstrated that altering the proangiogenic environment in the lung during bleomycin-induced pulmonary fibrosis with the IFN-inducible CXC chemokine, CXCL11, results in the following: (1) a reduction in total lung collagen and gene expression of procollagen type I; (2) amelioration of the histopatho…”
BackgroundInfluentialMechanisms of Disease: the role of immune cells in the pathogenesis of systemic sclerosis
Sakkas, L. I., Chikanza, I. C., & Platsoucas, C. D. (2006) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0346 · Cited by 163
“In small, randomized studies, IFN-γ had a small beneficial effect on skin fibrosis in patients with SSc, and improved lung function and survival in patients with idiopathic pulmonary fibrosis”
BackgroundNon-steroid agents for idiopathic pulmonary fibrosis
Spagnolo, P., Del Giovane, C., Luppi, F., Cerri, S., Balduzzi, S., Walters, E. H., D'Amico, R., & Richeldi, L. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003134.pub2 · Cited by 163
Roles of T lymphocytes in pulmonary fibrosis
Luzina, I. G., Todd, N. W., Iacono, A. T., & Atamas, S. P. (2008) · Journal of Leukocyte Biology · doi:10.1189/jlb.0707504 · Cited by 163
Nakagome, K. (2006) · Thorax · doi:10.1136/thx.2005.056317 · Cited by 159
“To study the kinetics of IL-10 gene delivery, mice were killed on days 1, 4, 7, 10, 13, and 20.”
MethodBeller, T. C., Maekawa, A., Friend, D. S., Austen, K. F., & Kanaoka, Y. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407057200 · Cited by 157
Yorke, J., Jones, P. W., & Swigris, J. J. (2010) · Thorax · doi:10.1136/thx.2010.139121 · Cited by 147
“For IPF there is currently no disease-specific measure of HRQL available so investigators have used generic or non-IPF respiratory-specific instruments to measure HRQL in multicentre trials.”
MethodIdiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years
Raghu, G. (2017) · European Respiratory Journal · doi:10.1183/13993003.01209-2017 · Cited by 146
Self-citationSalisbury, M. L., Lynch, D. A., van Beek, E. J. R., Kazerooni, E. A., Guo, J., Xia, M., Murray, S., Anstrom, K. J., Yow, E. S., Martínez, F. J., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201607-1385oc · Cited by 143
Symptoms and the early diagnosis of lung cancer
Birring, S., & Peake, M. D. (2005) · Thorax · doi:10.1136/thx.2004.032698 · Cited by 142
Idiopathic Pulmonary Fibrosis: Evolving Concepts
Ryu, J. H., Moua, T., Daniels, C. E., Hartman, T. E., Yi, E. S., Utz, J. P., & LIMPER, A. H. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.03.016 · Cited by 143
Glaspole, I., Chapman, S. A., Cooper, W. A., Ellis, S. J., Goh, N. S. L., Hopkins, P. M.-A., Macansh, S., Mahar, A. M., Moodley, Y. P., Paul, E. M., et al. (2017) · Respirology · doi:10.1111/resp.12989 · Cited by 142
Mulugeta, S., Nureki, S., & Beers, M. F. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00139.2015 · Cited by 138
Kalchiem‐Dekel, O., Galvin, J. R., BURKE, A. P., Atamas, S. P., & Todd, N. W. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120476 · Cited by 124
IPF: new insight on pathogenesis and treatment
Harari, S. A., & Caminati, A. (2010) · Allergy · doi:10.1111/j.1398-9995.2009.02305.x · Cited by 129
Lung function estimates in idiopathic pulmonary fibrosis: the potential for a simple classification
Egan, J. J., Martínez, F. J., Wells, A. U., & Williams, T. (2005) · Thorax · doi:10.1136/thx.2004.035436 · Cited by 119
Therapeutic Targeting of IL-4- and IL-13-Responsive Cells in Pulmonary Fibrosis
Jakubzick, C., Kunkel, S. L., Puri, R. K., & Hogaboam, C. M. (2004) · Immunologic Research · doi:10.1385/ir:30:3:339 · Cited by 118
“This adverse effect of IFN-γ treatment has been reported in a recent Phase III trial, which failed to show a beneficial effect of this treatment on progression-free survival, pulmonary function, or the quality of life ( 20 ).”
BackgroundEngineered vascular‐targeting antibody‐interferon‐γ fusion protein for cancer therapy
Ebbinghaus, C., Ronca, R., Kaspar, M., Grabulovski, D., Berndt, A., Kosmehl, H., Zardi, L., & Neri, D. (2005) · International Journal of Cancer · doi:10.1002/ijc.20952 · Cited by 117
Corte, T. J., Wort, S. J., Gatzoulis, M. Α., Macdonald, P., Hansell, D. M., & Wells, A. U. (2009) · Thorax · doi:10.1136/thx.2008.112847 · Cited by 124
“Age (years) 57 ± 12 Gender 28 female; 38 male Smoking (pack years) 27 non-smokers; 31 ex-smokers; 7 current smokers, 1 unknown Time from presentation (months) 33 (4-264)”
Salisbury, M. L., Xia, M., Zhou, Y., Murray, S., Tayob, N., Brown, K. K., Wells, A. U., Schmidt, S. L., Martínez, F. J., & Flaherty, K. R. (2015) · CHEST Journal · doi:10.1378/chest.15-0530 · Cited by 118
Self-citationRudd, R. M., Prescott, R. J., Chalmers, J. C., Johnston, I. D. A., & for the Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society (2007) · Thorax · doi:10.1136/thx.2005.045591 · Cited by 113
Effect of Emphysema Extent on Serial Lung Function in Patients with Idiopathic Pulmonary Fibrosis
Cottin, V., Hansell, D. M., Sverzellati, N., Weycker, D. A., Antoniou, K. M., Atwood, M., Oster, G., Kirchgaessler, K.-U., Collard, H. R., & Wells, A. U. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201612-2492oc · Cited by 115
Metadata
- Authors
- Raghu, G., Brown, K. K., Bradford, W. Z., Starko, K., Noble, P. W., Schwartz, D. A., & King, T. E.
- Affiliations
- University of Washington (US)
- National Jewish Health (US)
- Yale University (US)
- Duke University (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-01-08
- Volume
- 350
- Issue
- 2
- Pages
- 125-133
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2108226118
- Cited by
- 652
- References
- 34
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 8 · 2023: 15 · 2022: 15 · 2021: 16 · 2020: 15 · 2019: 17 · 2018: 11 · 2017: 22 · 2016: 21 · 2015: 29 · 2014: 20 · 2013: 38 · 2012: 39
- FWCI
- 54.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Keywords
- idiopathic pulmonary fibrosis, interferon gamma-1b, progression-free survival, corticosteroid-refractory disease, lung function, quality of life, mortality, pneumonia, constitutional symptoms, medication adherence
- MeSH terms
- Double-Blind Method, Female, Humans, Injections, Subcutaneous, Interferon-gamma, Male, Middle Aged, Pulmonary Fibrosis, Recombinant Proteins, Respiratory Function Tests, Respiratory Tract Infections, Risk, Proportional Hazards Models, Treatment Failure, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.